2026-03-24 11:31:16
COMPASS Pathways Reports Q4 and Full-Year 2025 Financial Results
Expected Stock impact: Slightly Positive
COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company focused on mental health innovation, announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported a net loss of $93.9 million for Q4 2025, compared to a net loss of $43.3 million in Q4 2024. The increase in net loss was primarily driven by a significant non-cash loss on fair value adjustments related to warrant liabilities, which amounted to $38.2 million. For the full year, COMPASS reported a net loss of $287.9 million, or $3.08 per share, compared to a net loss of $155.1 million, or $2.30 per share, in 2024. The company’s cash and cash equivalents stood at $149.6 million as of December 31, 2025, down from $165.1 million a year earlier. Despite the losses, COMPASS highlighted several positive developments, including the successful completion of a $150 million financing round in February 2026 and the initiation of a Phase 2b/3 trial for COMP360 in PTSD following FDA acceptance of its IND application. The company is also preparing for a rolling submission of its New Drug Application (NDA) for COMP360, which is expected to be completed in Q4 2026. CEO Kabir Nath emphasized the potential of COMP360 to redefine treatment for patients with treatment-resistant depression (TRD), noting its rapid onset of action and durability of effect. The company is advancing its commercial readiness plans to ensure a seamless launch across diverse healthcare settings. Overall, while the financial results reflect significant losses, the strategic advancements and ongoing clinical trials position COMPASS Pathways for potential future success in the mental health space.
